Catherine M. De Lara

Oxford, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa.

Evaluation of Hepatitis B core-related antigen (HBcrAg) as a biomarker in cohorts from the United Kingdom and South Africa.

Journal: The Journal of infection

Published: March 04, 2025

Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.

Whole genome sequencing of hepatitis B virus using tiled amplicon (HEPTILE) and probe based enrichment on Illumina and Nanopore platforms.

Journal: Scientific reports

Published: September 10, 2024

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

T cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses.

Journal: Nature communications

Published: October 02, 2020

Single-cell transcriptome analysis of CD8 + T-cell memory inflation.

Single-cell transcriptome analysis of CD8 + T-cell memory inflation.

Journal: Wellcome open research

Published: April 26, 2019

Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure.

Characterizing Hepatitis C Virus-Specific CD4+ T Cells Following Viral-Vectored Vaccination, Directly Acting Antivirals, and Spontaneous Viral Cure.

Journal: Hepatology (Baltimore, Md.)

Published: April 07, 2019

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.

First-in-Human Randomized Study to Assess the Safety and Immunogenicity of an Investigational Respiratory Syncytial Virus (RSV) Vaccine Based on Chimpanzee-Adenovirus-155 Viral Vector-Expressing RSV Fusion, Nucleocapsid, and Antitermination Viral Proteins in Healthy Adults.

Journal: Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Published: December 31, 2018

Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV).

Illumina and Nanopore methods for whole genome sequencing of hepatitis B virus (HBV).

Journal: Scientific reports

Published: November 24, 2018

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.

Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults.

Journal: The Journal of infection

Published: November 20, 2018

Humoral and cellular immunity to RSV in infants, children and adults.

Humoral and cellular immunity to RSV in infants, children and adults.

Journal: Vaccine

Published: April 10, 2018

Adenoviral vaccine induction of CD8+ T cell memory inflation: Impact of co-infection and infection order.

Adenoviral vaccine induction of CD8+ T cell memory inflation: Impact of co-infection and infection order.

Journal: PLoS pathogens

Published: July 03, 2017

MAIT cells are activated during human viral infections.

MAIT cells are activated during human viral infections.

Journal: Nature communications

Published: December 01, 2015

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.

Safety and immunogenicity of novel respiratory syncytial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open-label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults.

Journal: BMJ open

Published: October 30, 2015

Showing 1-12 of 17

Last Updated: 09/26/2026